The hypothesis was tested that tumors with a primarily high expression level of Coxsackie adenovirus receptor may be more suitable for oncolytic therapy in SCLC.224 A recombinant Coxsackievirus B3 (CVB3), which is powerful in destroying TP53/RB1-mutant SCLC, was generated to reduce the toxicity toward normal tissues. This evidence concerns the gene TP53 and small cell lung carcinoma.